1
|
Krunal Vishavadia KV, Sandip Solanki SS, Hiren Prajapati HP, Madhu Sharma MS. [Assessment of prescribing practices in overactive bladder pharmacotherapy across different specialties of India: a prescription trend analysis]. UROLOGIIA (MOSCOW, RUSSIA : 1999) 2023:66-72. [PMID: 37401707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 07/05/2023]
Abstract
PURPOSE To assess the prescribing practices for overactive bladder (OAB) pharmacotherapy based on the prescription trend analysis across different specialties of India. METHOD s: IQVIA (Quintiles and IMS Health) secondary sales audit (SSA), as well as a prescription audit for antimuscarinics and beta-3 adrenoceptor agonists (mirabegron) from 2014 to 2021, were analyzed. The data includes SSA data of various antimuscarinics like solifenacin, oxybutynin, tolterodine, darifenacin, trospium and mirabegron change in the prescription trend of antimuscarinics and mirabegron across different specialties; prescribers overlap analysis for solifenacin and mirabegron among Indian urologists were also analyzed. RESULTS Urologists prescription rates of OAB drugs were 65% in 2016 and 54% in 2021. The rate of OAB medication prescription by non-urologist was highest from the surgeon (11%), followed by gynecologists (9%) and consultant physicians (8%) in 2021. In addition, among OAB medication prescription rates for antimuscarinics were 100% in 2016 and 58% in 2021 whereas for mirabegron, it was 0% in 2016 and 42% in 2021. Solifenacin was most frequently prescribed anticholinergics, followed by oxybutynin, tolterodine, darifenacin, and trospium. The proportion of prescribers of OAB medication among urologists was 38% in 2016 and 33% in 2021. Exclusive prescribers of solifenacin were 748 in 2018 and 739 in 2021 at the urologist, whereas for mirabegron, it was 961 in 2018 and 934 in 2021. The compound annual growth rate for prescription of the last 6 years (from 2016-2021) for solifenacin and mirabegron was -3% and 8% respectively. CONCLUSIONS Urology remained a top prescribing specialty for OAB drugs, although prescription share increased at surgeon and consultant physician. OAB medicines prescriptions by urologists are shifting from leading antimuscarinic solifenacin to beta-agonist mirabegron. Data from this study will ultimately lead to the OAB medication preference by the specialist that could lead to more advanced OAB management.
Collapse
Affiliation(s)
- Krunal Vishavadia Krunal Vishavadia
- Gujarat Technological University, Ahmedabad, India
- SIIB, Pune, Maharashtra, India
- International Journal of Diabetes and Endocrinology, Ahmedabad, Gujarat, India
- Department of Anaesthesiology, Sardar Vallabhbhai Patel Institute of Medical Science and Research, Ellisbridge, Ahmedabad, Gujarat, India
| | - Sandip Solanki Sandip Solanki
- Gujarat Technological University, Ahmedabad, India
- SIIB, Pune, Maharashtra, India
- International Journal of Diabetes and Endocrinology, Ahmedabad, Gujarat, India
- Department of Anaesthesiology, Sardar Vallabhbhai Patel Institute of Medical Science and Research, Ellisbridge, Ahmedabad, Gujarat, India
| | - Hiren Prajapati Hiren Prajapati
- Gujarat Technological University, Ahmedabad, India
- SIIB, Pune, Maharashtra, India
- International Journal of Diabetes and Endocrinology, Ahmedabad, Gujarat, India
- Department of Anaesthesiology, Sardar Vallabhbhai Patel Institute of Medical Science and Research, Ellisbridge, Ahmedabad, Gujarat, India
| | - Madhu Sharma Madhu Sharma
- Gujarat Technological University, Ahmedabad, India
- SIIB, Pune, Maharashtra, India
- International Journal of Diabetes and Endocrinology, Ahmedabad, Gujarat, India
- Department of Anaesthesiology, Sardar Vallabhbhai Patel Institute of Medical Science and Research, Ellisbridge, Ahmedabad, Gujarat, India
| |
Collapse
|
2
|
Pontiroli AE, Rizzo M, Tagliabue E. Use of glucagon in severe hypoglycemia is scarce in most countries, and has not been expanded by new ready-to-use glucagons. Diabetol Metab Syndr 2022; 14:193. [PMID: 36550552 PMCID: PMC9780089 DOI: 10.1186/s13098-022-00950-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 11/11/2022] [Indexed: 12/24/2022] Open
Abstract
Glucagon (traditional kits for intramuscular administration, Glucagon and Glucagen), although recommended as a remedy for severe hypoglycemia (SH), has been reported to be under-utilized, likely because of technical problems. The aims of this study were to evaluate the use of glucagon in persons with type 1 diabetes in several countries, and to investigate if the availability of new ready-to-use glucagons (Baqsimi, Gvoke, Zegalogue, years 2019 to 2021) has expanded the overall use of glucagon. The source of data was IQVIA-MIDAS (units of glucagon sold), while data on persons with type 1 diabetes in countries were derived from IDF Diabetes Atlas. The use of glucagon has been steady from 2014 to 2019, with a small but significant increase from 2019 to 2021, paradoxically only in countries where new ready-to-use glucagons were not available. The use of glucagon has always been ten fold greater in countries where new ready-to-use glucagons became available than in the other countries (population 108,000,000 vs 28,100,000, 480,291 vs 182,018 persons with type 1 diabetes). A significant correlation was observed in all years between units of glucagon and persons with type 1 diabetes. Availability of new ready-to-use glucagons was associated with a small increase of sales, due only to new ready-to-use glucagons themselves. The use of glucagon (any type) remains low, approximately 1/10 of persons with type 1 diabetes. We conclude that use of glucagon is scarce in most countries, and so far has not been expanded by new ready-to-use glucagons such as the ones considered in this study.
Collapse
Affiliation(s)
- Antonio E. Pontiroli
- Dipartimento Di Scienze Della Salute, Università Degli Studi Di Milano, Milan, Italy
| | - Manfredi Rizzo
- Promise Department, School of Medicine, University of Palermo, Palermo, Italy
| | - Elena Tagliabue
- Value-Based Healthcare Unit, IRCCS MultiMedica, Milan, Italy
| |
Collapse
|